Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-respondersChristian Gytz Ammitzbøll, Anne Troldborg, Mads Lamm Larsen et al.|Lara D. Veeken|2022Cited by 16
COVID‐19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post‐Pandemic Concerns About the Impact of RituximabChristian Gytz Ammitzbøll, Anne Troldborg, Ellen‐Margrethe Hauge et al.|ACR Open Rheumatology|2024Cited by 5
Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patientsChristian Gytz Ammitzbøll, Anne Troldborg, Fruzsina Szabados et al.|Clinical and Experimental Rheumatology|2023Cited by 3